

## **Curriculum Vitae**

### **Aurélie Velay-Rusch, PD, PhD**

**Date of Birth**                    October 29 1979, Le Mans, France  
French Nationality

**Current position**            Associate Professor of Medicine– Attending Physician (MCU-PH), Laboratoire de Virologie Médicale, Hopitaux Universitaires de Strasbourg

#### **Appointments and Positions – Clinical**

09/01/2019-                    Associate Professor of Medicine– Attending Physician (MCU-PH), Laboratoire de Virologie Médicale, Hopitaux Universitaires de Strasbourg  
2014-2019                      Praticien attaché, Virologie Médicale des Hôpitaux Universitaires de Strasbourg  
2011-2014                      Resident (AHU), Laboratoire de Virologie Médicale, CHU Nancy-Brabois, France.  
2007-2011                      Intern in « Medecine Biology », Hôpitaux Universitaires Strasbourg, France  
2006-2007                      Intern in « Medecine Biology », CHU Besançon, France

#### **Education**

2016                              Diplôme Interuniversitaire de pédagogie médicale, Université de Strasbourg  
2015                              Doctor of Science (PhD), Université de Lorraine, Ecole Doctorale Biologie-Santé-Environnement.  
2011                              Doctor of Pharmacy (PD), DES Biologie Médicale, Faculté de Pharmacie, Université de Strasbourg, France  
2010                              Master's degree. Physiopathologie moléculaire et cellulaire, Université de Strasbourg.  
2009                              Diplôme Universitaire d'antibiothérapie, Université de Strasbourg  
2000-2006                      Pharmaceutical School Université d'Angers  
1999-2000                      Faculty of Biology Université d'Angers  
1997-1999                      Faculty of Medecine, Université d'Angers  
1997                              Baccalauréat général scientifique (Physique-chimie), lycée Montesquieu (72), mention assez-bien

#### **Teaching**

##### **Lectures and seminars in basic and medical virology:**

- University of Strasbourg Medical School
- Master programs
- Postgraduate education medical doctors

#### **Reviewer for Scientific Journals**

J. Clin. Virol., Eurosurveillance

#### **Nationales and internationales Communications (Since 2009)**

23 orales communications et 25 posters

## Main publications (Since 2009)

1. [Velay A](#), Schramm F, Gaudias J, Jaulhac B, Riegel P. Culture with BACTEC Peds Plus bottle compared with conventional media for the detection of bacteria in tissue samples from orthopedic surgery. *Diagn Microbiol Infect Dis*. 2010; 68(1):83-5. (IF : 2.26)
2. Jeulin H, [Velay A](#), Murray J, Schvoerer E. Hepatitis B and hepatitis C virus envelope glycoproteins: do their key roles in cellular viral entry and host immune response have clinical impact? (Invited Review) *World J Gastroenterol* 2013;19(5):654-64. (IF: 2.433)
3. Schvoerer E, Moenne-Loccoz R, Murray JM, [Velay A](#), Turek M, Fofana I, Fafi-Kremer S, Erba AC, Habersetzer F, Doffoël M, Gut JP, Zeisel MB, Stoll-Keller F, Baumert TF. Hepatitis C virus envelope glycoprotein signatures modulating viral entry and neutralization are associated with treatment failure. *J Infect Dis*. 2013;207(8):1306-15. (IF : 5.778)
4. Murray JM, Moenne-Loccoz R, [Velay A](#), Habersetzer F, Doffoël M, Gut JP, Zeisel MB, Stoll-Keller F, Baumert TF, Schvoerer E. Hepatitis C virus envelope features in genotypes 1a and 1b that determine response to antiviral therapy assessed through optimal covariance networks. *PLoS One* 2013;8(6):e67254. (IF: 3.534)
5. Jeulin H, Foissac M, Boyer L, Agrinier N, Perrier P, [Velay A](#), Goehring F, Henard S, Rabaud C, May T, Schvoerer E. Real life Rilpivirine-resistance and potential emergence of a E138A positive HIV strain in Nancy, North-eastern France. *J Antimicrob Chemother*. 2014 ;69(11):3095-102. (IF : 5.313)
6. Larrat S, Vallet S, David-Tchouda S, Caporossi A, Margier J, Ramière C, Scholtes C, Haïm-Boukoba S, Roque-Afonso AM, Besse B, André-Garnier E, Mohamed S, Halfon P, Pivert A, LeGuillou-Guillemette H, Abravanel F, Guivarch M, Mackiewicz V, Lada O, Mourez T, Plantier JC, Baazia Y, Alain S, Hantz S, Thibault V, Gaudy-Graffin C, Bouvet D, Mirand A, Henquell C, Gozlan J, Lagathu G, Pronier C, [Velay A](#), Schvoerer E, Trimoulet P, Fleury H, Bouvier-Alias M, Brochot E, Duverlie G, Maylin S, Gouriou S, Pawlotsky JM, Morand P. Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin. *J Clin Microbiol*. 2015; 53(7):2195-202. (IF : 3.631)
7. [Velay A](#), Jeulin H, Eschlimann M, Malvé B, Goehring F, Bensenane M, Fripiat JP, Abraham P, Ismail AM, Murray JM, Combet C, Zoulim F, Bronowicki JP, Schvoerer E. Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy. *J Viral Hepat*. 2016; 23(5):387-98. (IF : 4.122)
8. Feugeas J, Mory S, Jeulin H, [Velay A](#), Pertek JP, Ladriere M, Losser MR. Herpes simplex virus type 1 hepatitis due to primary infection in a pancreas-kidney transplant recipient. *J Clin Virol*. 2016; 80:57-9. (IF: 3.051)
9. Barth H, Solis M, Kack-Kack W, Soulier E, [Velay A](#), Fafi-Kremer S. In Vitro and In Vivo Models for the Study of Human Polyomavirus Infection. *Viruses*. 2016; 8(10). pii: E292. (IF : 3.465)
10. Lafontaine S, Prin-Mathieu C, [Velay A](#), Agulles O, Schvoerer E, Jeulin H. Evaluation of Virological Microparticle Enzyme Immunoassay According to the ISO 15189: Real-Life Experience in a University Hospital. *Clin Lab*. 2016;62(3):275-84. (IF: 0.84)
11. Lepiller Q, Solis M, [Velay A](#), Gantner P, Sueur C, Stoll-Keller F, Barth H, Fafi-Kremer S. Problem-based learning in laboratory medicine resident education: a satisfaction survey. *Ann Biol Clin*. 2017; 75(2):181-92. (IF: 0.284)
12. Gantner P, [Velay A](#), Guigue N, Barth H, Wendling MJ, Delaugerre C, Fafi-Kremer S. Performance of the Liaison® XL Murex rechTLV-I/II Immunoassay in the Detection of HTLV-1/2 Antibodies in Serum. *Clin Lab*. 2017 ;63(5):997-1001. (IF: 0.84)
13. Argemi X, Martin V, Loux V, Dahyot S, Lebeurre J, Guffroy A, Martin M, [Velay A](#), Keller D, Riegel P, Hansmann Y, Paul N, Prévost G. Whole-Genome Sequencing of Seven Strains of Staphylococcus lugdunensis Allows Identification of Mobile Genetic Elements. *Genome Biol Evol*. 2017;9(5). (IF: 3.979)
14. Eschlimann M, Malvé B, [Velay A](#), Fenaux H, Berger S, Fripiat JP, Zoulim F, Bensenane M, Bronowicki JP, Goehring F, May T, Jeulin H, Schvoerer E. The variability of hepatitis B envelope is associated with HBs antigen persistence in either chronic or acute HBV genotype A infection. *J Clin Virol* 2017; 94:115-22. (IF: 3.051)
15. [Velay A](#), Kack-Kack W, Abravanel F, Lhomme S, Leyendecker P, Kremer L, Chamouard P, Izopet J, Fafi-Kremer S, Barth H. Parsonage-Turner syndrome due to autochthonous acute genotype 3f hepatitis E virus infection in a nonimmunocompromised 55-year-old patient. *J Neurovirol*. 2017;23(4):615-20. (IF : 3.206)
16. [Velay A](#), Solis M, Kack-Kack W, Gantner P, Maquart M, Martinot M, Augereau O, De Briel D, Kieffer P, Lohmann C, Poveda JD, Cart-Tanneur E, Argemi X, Leparç-Goffart I, de Martino S, Jaulhac B, Raguet S, Wendling MJ, Hansmann Y, Fafi-Kremer S. A new hot spot for tick-borne encephalitis (TBE): A marked increase of TBE cases in France in 2016. *Ticks Tick Borne Dis*. 2018; 9(1):120-5. (IF: 3.23)
17. Solis M, [Velay A](#), Porcher R, Domingo-Calap P, Soulier E, Joly M, Meddeb M, Kack-Kack W, Moulin B, Bahram S, Stoll-Keller F, Barth H, Caillard S, Fafi-Kremer S. Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy. *J Am Soc Nephrol*. 2018 ;29(1):326-34. (IF: 8.966)
18. [Velay A](#), Solis M, Barth H, Sohn V, Moncollin A, Neeb A, Wendling MJ, Fafi-Kremer S. Comparison of six commercial tick-borne encephalitis IgM and IgG ELISA kits and the molecular characterization of their antigenic design. *Diagn Microbiol Infect dis*, 2018 ;90(4):286-92. (IF: 2.40)
19. Solis M, [Velay A](#), Moulin B, Caillard S, Fafi-Kremer S. Strengthening the Humoral Response: A Promising Anti-Polyomavirus Preventive Strategy (letter to the editor). *J Am Soc Nephrol*, 2018 ;29(5):1578. (IF: 8.966)
20. Solis M, [Velay A](#), Gantner P, Bausson J, Filiputti A, Freitag R, Moulin B, Caillard S, Fafi-Kremer S. Long-term follow-up of Torquetenovirus viremia after kidney transplantation. *J Infect*. 2019;79(1):56-60. (IF: 4.603)
21. [Velay A](#), Paz M, Cesbron M, Gantner P, Solis M, Soulier E, Argemi X, Martinot M, Hansmann Y, Fafi-Kremer S. Tick-borne encephalitis virus: molecular determinants of neuropathogenesis of an emerging pathogen *Crit Rev Microbiol*. 2019;45(4):472-493. (IF: 4.738)
22. [Velay A](#), Solis M, Benotmane I, Gantner P, Soulier E, Barth H, Moulin B, Caillard S, Fafi-Kremer S. In vitro and ex vivo characterization of anti-BK virus neutralizing antibodies in intravenous immunoglobulins: benefits for kidney transplant recipients. *Antimicrob Agents Chemother*. 2019;63(8). pii: e00393-19. (IF: 4.255)
23. Botelho-Nevers E, Gagneux-Brunon A, [Velay A](#), Guerbois-Galla M, Grard G, Bretagne C, Mailles A, Verhoeven PO, Pozzetto B, Gonzalo S, Fafi-Kremer S, Leparç-Goffart I, Pillet S. Tick-Borne Encephalitis in Auvergne-Rhône-Alpes Region, France, 2017-2018. *Emerg Infect Dis*. 2019 ;25(10):1944-8. (IF: 7.422)
24. Solis M, Gallais F, [Velay A](#), Fafi-Kremer S. BK-virus and pathophysiology of associated diseases. *Virologie*. 2019 ;23(1):7-22.